Uchendu, I.K.; Ngaha Tchawe, Y.S.; Angelina V., Z.; Sangadzhieva, Z.D.; S. Rusanov, A.; N. Bagmet, L.; D. Sanikovich, V.; Nikitina, N.M.; Ikebunwa, O.A.; Okoroiwu, H.U.; Kazeem, O.B.; I. Sekacheva, M. Epidemiology Patterns of Renal Cell Carcinoma Worldwide: Examining Risk Factors and Contemporary Immunotherapy Approaches. Preprints2023, 2023101757. https://doi.org/10.20944/preprints202310.1757.v1
APA Style
Uchendu, I.K., Ngaha Tchawe, Y.S., Angelina V., Z., Sangadzhieva, Z.D., S. Rusanov, A., N. Bagmet, L., D. Sanikovich, V., Nikitina, N.M., Ikebunwa, O.A., Okoroiwu, H.U., Kazeem, O.B., & I. Sekacheva, M. (2023). Epidemiology Patterns of Renal Cell Carcinoma Worldwide: Examining Risk Factors and Contemporary Immunotherapy Approaches. Preprints. https://doi.org/10.20944/preprints202310.1757.v1
Chicago/Turabian Style
Uchendu, I.K., Olokodana Babatunde Kazeem and Marina I. Sekacheva. 2023 "Epidemiology Patterns of Renal Cell Carcinoma Worldwide: Examining Risk Factors and Contemporary Immunotherapy Approaches" Preprints. https://doi.org/10.20944/preprints202310.1757.v1
Abstract
Renal cell carcinoma (RCC), alternative term for kidney cancer, is becoming more common worldwide each year, and there are many different contributing factors. Among all cancers, RCC is the 14th most prevalent; and it ranks as the 14th and 9th most prevalent cancer overall for women and men respectively. RCC cases increased by more than 430,000 in 2020. While disease burdens are highest in Eastern Europe (Belarus and Russia) and North America (Canada and the United States), Africa, Asia, and Latin America are predicted to report increase in prevalence as these regions embrace change in lifestyle. The majority of RCC cases are accidentally found on imaging, and survival is greatly impacted by the disease stage at diagnosis, with a metastatic cancer having a 5-year survival rate of 12%. As a consequence of early discovery and more improved treatments, RCC mortality has declined. The key epidemiologic variables of RCC include vast regional and geographical heterogeneity in prevalence rates, and the cause is largely unclear. Recognized risk factors include smoking, being overweight, having previous episodes of hypertension, and suffering chronic renal illness. Unexpectedly swift, RCC diagnosis and therapy have advanced. RCC prevalence continues to rise although survival rates have sharply improved. Cancer survival and treatment have improved, and more gains are projected as a result of clinical and translational research. In this review, kidney cancer statistics and recent literatures are examined on a global scale. It covered aspects of kidney cancer, including its epidemiology, causes, risk factors, current immunotherapy, chances for prevention, and future planning.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
*
